Macomb considers insurance issues
Maomb discussed different insurance issues, and heard from a resident petitioning for freezing water & sewer rates at the committee meeting Monday.
Stay updated with breaking news from Dana Walker. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Maomb discussed different insurance issues, and heard from a resident petitioning for freezing water & sewer rates at the committee meeting Monday.
Two Opdivo -based therapies are now authorized for first-line treatment of patients with advanced renal cell carcinoma in the European Union: Opdivo plus Yervoy in combination with Cabometyx Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo Cabometyx ® (cabozantinib) for the first-line treatment of adults with advanced renal cell carcinoma (RCC). The EC’s decision is based on results from the Phase 3 CheckMate -9ER trial, which demonstrated superior efficacy with Opdivo in combination with Cabometyx versus suni...
European Commission approves Opdivo plus Cambometyx for advanced kidney cancer Checkpoint inhibitor plus tyrosine kinase inhibitor approved for the first-line treatment of advanced renal cell carcinoma The European Commission (EC) has approved a combination of Bristol Myers Squibb’s (BMS) Opdivo with Ipsen’s Cabometyx for the first-line treatment of advanced renal cell carcinoma (RCC) – the most common form of kidney cancer. BMS’ checkpoint inhibitor Opdivo (nivolumab) is already approved in combination with CTLA-4 inhibitor Yervoy (ipilimumab) as an initial treatment for advanced RC...
Bristol Myers' Nivolumab Approved By EU For Kidney Cancer Treatment NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb Co. (BMY) Wednesday said the European Commission has approved its drug nivolumab in combination with cabozantinib as a treatment for patients with advanced renal cell carcinoma. The New York-based pharmaceutical company said the EC's decision was based on results from a late-stage trial, which demonstrated superior efficacy with nivolumab in combination with Cabometyx versus sunitinib across three key endpoints: progression-free survival and objective response rate and overall su...
How Michigan’s downtowns survived the pandemic Updated 12:25 PM; Facebook Share Within days of the first COVID-19 case being reported in Michigan, Sue Huggett walked door-to-door asking downtown Kalamazoo businesses to participate in the Gift Card Stimulus program. As the events director for the Kalamazoo Downtown Partnership, Huggett’s duties became solely focused on business support. Doors were closing and the weight of the novel coronavirus was setting in. In five days, Huggett collected 2,000 gift cards from 66 businesses. She set up a mailing station in her home and sent the gift ca...